Indevus News (NASDAQ:IDEV)
| Latest Indevus Pharmaceuticals News Headlines | | Date | Time | Source | | | 07/02/2008 | 10:00AM | PRNUS | BeaconEquity.com Issues TraderNotes on Active Stocks: WWAT, UCBH, PMTI, XMSR, IDEV, F, BUSE, HYGS
DALLAS, July 2 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's TraderNotes include: WorldWater & Solar Technologies Corp. (OTC:WWAT) (BULLETIN BOARD:... More...>> |
| 06/30/2008 | 10:21AM | PRNUS | Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Company Announces Revised Operating Plan to Respond to NEBIDO Delay
LEXINGTON, Mass., June 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NEBIDO(R) related to a New Drug Application... More...>> |
| 06/12/2008 | 8:00AM | PRNUS | Indevus Announces Management Changes
Company Begins Process to Restore Shareholder Value Following NEBIDO(R) Delay
LEXINGTON, Mass., June 12 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that Glenn L. Cooper, MD, its chairman and chief executive officer is postponing his previously-announced retirement to lead the... More...>> |
| 06/04/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
Company Expects FDA to Request Additional Safety Study Prior to Approval
LEXINGTON, Mass., June 4 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the NDA filing for NEBIDO(R), the Company expects... More...>> |
| 05/22/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc.
LEXINGTON, Mass., May 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced the signing of a License Agreement with Allergan Inc., a Canadian affiliate of Allergan, Inc., based in Irvine, CA, granting Allergan the right to market SANCTURA XR(TM) (trospium chloride extended release... More...>> |
| 05/20/2008 | 4:15PM | PRNUS | Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
94 Percent of Men Maintained Normal Testosterone Levels Throughout Treatment
LEXINGTON, Mass., May 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that data on NEBIDO(R) (testosterone undecanoate), an investigational, long-acting intramuscular injection for the treatment of hypogonadism... More...>> |
| 05/15/2008 | 4:15PM | PRNUS | Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
LEXINGTON, Mass., May 15 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that the Company will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on May 19, 2008 at 4:55 p.m. local time (10:55 a.m. EDT) and at the 2008 UBS Global Generic and Specialty Pharmaceuticals... More...>> |
| 05/05/2008 | 4:00PM | PRNUS | Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Pube
LEXINGTON, Mass., May 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at... More...>> |
| 04/30/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Announces Second Quarter Fiscal 2008 Financial Results
LEXINGTON, Mass., April 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced its consolidated results of operations for the second quarter of fiscal 2008, ended March 31, 2008. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow... More...>> |
| 04/23/2008 | 4:00PM | PRNUS | Indevus to Announce Second Quarter Fiscal 2008 Financial Results on Wednesday, April 30, 2008
Company to Conduct Conference Call and Webcast
LEXINGTON, Mass., April 23 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) will announce its second quarter fiscal 2008 financial results in a press release to be issued before market open on Wednesday, April 30, 2008. The Company will host a conference... More...>> |
| 04/03/2008 | 4:05PM | PRNUS | Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Transaction Significantly Expands Global Product Potential
LEXINGTON, Mass., April 3, 2008 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced the signing of a License, Supply and Distribution Agreement with Orion Corporation granting Orion the rights to market VANTAS(R) (histrelin... More...>> |
| 03/20/2008 | 8:00AM | PRNUS | 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
Indevus encouraging other companies across the country to hold their events in New Orleans and to bring their helping hearts and hands
LEXINGTON, Mass., March 20 /PRNewswire-FirstCall/ -- As part of its annual sales meeting being held in New Orleans for the first time, Indevus Pharmaceuticals (NASDAQ:IDEV), a specialty... More...>> |
| 03/11/2008 | 4:00PM | PRNUS | Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
LEXINGTON, Mass., March 11 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced the Company will be presenting at the Cowen and Company 28th Annual Health Care Conference, on Tuesday, March 18, 2008 at 1:40 pm ET. The conference is being held in Boston, Massachusetts. The presentation... More...>> |
| 03/03/2008 | 4:15PM | PRNUS | Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
LEXINGTON, Mass., March 3 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today that Glenn L. Cooper, M.D. plans to retire as Indevus' Chief Executive Officer and Chairman of the Board of Directors later this year on or prior to September 1, 2008.
Dr. Cooper said, "After 15 years at... More...>> |
| 02/15/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Provides Update on PRO 2000 Program
LEXINGTON, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) announced today that they have been advised by the United Kingdom's Medical Research Council (MRC) that after review of data from the Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for HIV... More...>> |
| 02/07/2008 | 8:00AM | PRNUS | Indevus Pharmaceuticals Announces First Quarter Fiscal 2008 Financial Results
LEXINGTON, Mass., Feb. 7 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced its consolidated results of operations for the first quarter of fiscal 2008, ended December 31, 2007. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow... More...>> |
| 01/31/2008 | 8:00AM | PRNUS | Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
Company to Conduct Conference Call and Webcast
LEXINGTON, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) will announce its first quarter fiscal 2008 financial results in a press release to be issued before market open on Thursday, February 7, 2008. The Company will host a conference... More...>> |
| 01/22/2008 | 8:30AM | PRNUS | Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Company Files Additional Data to the NEBIDO NDA
LEXINGTON, Mass., Jan. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced additional positive results from its Phase III program for NEBIDO (testosterone undecanoate), a long-acting injectable testosterone therapy under development... More...>> |
| 12/20/2007 | 3:35PM | PRNUS | Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
VANTAS(R) to be Only Once-Yearly Implant for Prostate Cancer in U.S. Market
LEXINGTON, Mass., Dec. 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today commented on the announcement by Bayer Healthcare that they would discontinue marketing their product Viadur(R) (leuprolide acetate implant... More...>> |
| 12/19/2007 | 4:15PM | PRNUS | Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
VALSTAR-specific Issues Have Been Resolved; Remaining Issues Pertain to cGMP Compliance of Third-party Manufacturing Facility
LEXINGTON, Mass., Dec. 19 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration... More...>> |
|
|
|